NF-κB inhibitor comprising phenylmethyl benzoquinone...

Details NF-κB inhibitor comprising phenylmethyl benzoquinone... NF-κB inhibitor comprising phenylmethyl benzoquinone...

2005-09-13

2005-09-13

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ketone doai

C514S532000, C514S544000, C514S570000, C514S621000, C514S622000, C514S679000, C514S733000, C514S736000, C552S293000, C560S051000, C560S057000, C544S056000, C544S120000, C546S257000, C562S459000, C562S468000

Reexamination Certificate

active

06943196

ABSTRACT:
An NF-κB inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R1, R2, and R3are each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; R4is H, hydroxymethyl, alkyl, or carboxyl which is optionally esterified or amidated; Z is represented by the formula (A); and, n is an integer from 0 to 6, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 6703421 (2004-03-01), Nunokawa et al.
patent: 2004/0030129 (2004-02-01), Nunokawa et al.
patent: 0864648 (1998-09-01), None
patent: 62-286949 (1987-12-01), None
patent: 4-226937 (1992-08-01), None
patent: 98/12313 (1998-03-01), None
Suzuki et al. Chem. Pharm.Bull., 1996, vol. 41(1), 139-144.
Database WPI, Section Ch, Week 199602, Derwent Publication Ltd., XP 002240470 & JP 07291860, Nov. 7, 1995, Abstract.
Database WPI, Section Ch, Week 199602, Derwent Publications Ltd., XP 002240471 & JP 07291859, Nov. 7, 1995, Abstract.
Salvador Moncada, M.D., et al., “The L-Arginine-Nitric Oxide Pathway,” The New England Journal of Medicine, vol. 329, No. 27, pp. 2002-2012, 1993.
Ulrich Forstermann et al, “Properties, Cellular Distribution and Expressional Control,” Biochemical Pharmacology, vol. 50, No. 9, pp. 1321-1332, 1995.
V. Cattell et al, “Inducible Nitric Oxide Synthase in Inflammation,” Histochemical Journal, vol. 27, pp. 777-784, 1995.
Andreas K. Nussler et al, “Inflammation, Immunoregulation, and Inducible Nitric Oxide Synthase,” Journal of Leukocyte Biology, vol. 54, pp. 171-178, 1993.
S. Moncada et al, “Molecular Mechanisms and Therapeutic Strategies Related to Nitric Oxide,” The FASEB Journal, vol. 9, pp. 1319-1330, 1995.
Xiao-qing Wei et al, “Altered Immune Responses in Mice Lacking Inducible Nitric Oxide Synthase,” Nature, vol. 375, pp. 408-411, 1995.
Jill E. Ogden et al, “Inhibition of Nitric Oxide Synthase—Potential for a Novel Class of Therapeutic Agent,” Tibtech, vol. 13, pp. 70-78, 1995.
R. Davis Manning, Jr. et al, “Cardiovascular Responses to Long-Term Blockade of Nitric Oxide Synthesis,” Hypertension, vol. 22, No. 1, pp. 40-48, 1993.
Garry J. Southan et al, “Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms,” Biochemical Pharmacology, vol. 51, pp. 383-394, 1996.
Pierre Vassalli et al, “The Pathophysiology of Tumor Necrosis Factors,” Annu. Rev. Immunol., vol. 10, pp. 411-452, 1992.
Yasutoshi Muto et al, “Enhanced Tumour Necrosis Factor and Interleukin-1 in Fulminant Hepatic Failure,” The Lancet, pp. 72-74, 1998.
Mohammad K. Sharief, M.B. et al, “Association Between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis,” vol. 325, No. 7, pp. 467-472, 1991.
Ciro Tetta et al, “Tumour Necrosis Factor in Serum and Synovial Fluid of Patients with Active and Severe Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, vol. 49, pp. 665-667, 1990.
G. Venn et al, “Elevated Synovial Fluid Leels of Interleukin-6 and Tumor Necrosis Factor Associated with Early Experimental Canine Osteoarthritis,” Arthritis and Rheumatism, vol. 36, No. 6, pp. 819-826, 1993.
Michael J. Elliott et al, “Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor α (cA2) in pateitns with Rheumatoid Arthritis,” The Lancet, vol. 344, pp. 1125-1127, 1994.
Michael J. Elliott et al, “Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor α (cA2) Versus Placebo in Rheumatoid Arthritis,” The Lancet, vol. 344, pp. 1105-1110, 1994.
E. C. C. Rankin et al, “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis,” British Journal of Rheumatology, vol. 34, pp. 334-342, 1995.
Jean-Louis Vincent, M.D. et al, “Administration of Anti-TNF Antibody Improves Left Ventricular Function in Septic Shock Patients,” Chest, vol. 101, No. 3, pp. 810-815, 1992.
L.B. Hinshaw et al., “Survival of Primates in LD100Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFα),” Circulatory Shock, vol. 30, pp. 279-292, 1990.
U. Nyman et al, “Amelioration of Collagen II-Induced Arthritis in Rats by the Type IV Phosphodiesterase Inhibitor Rolipram,” Clin. Exp. Immunol. vol. 108, pp. 415-419, 1997.
Timothy S. Blackwell et al, “The Role of Nuclear Factor-κB in Cytokine Gene Regulation,” Am. J. Respir. Cell Mol. Biol., vol. 17, pp. 3-9, 1997.
C. Victor Jongeneel, “Regulation of the TNFα Gene,” Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies, pp. 367-381, 1994.
Qiao-wen Xie et al, “Role of Transcription Factor NF-κB/Rel in Induction of Nitric Oxide Synthase,” The Journal or Biological Chemistry, vol. 269, No. 7, pp. 4705-4708, 1994.
Youichi Nunokawa et al, “Human Inducible Nitric Oxide Synthase Gene is Transcriptionally Regulated by Nuclear Factor-κB Dependent Mechanism,” Biochemical and Biophysical Research Communications, vol. 223, pp. 347-352, 1996.
Tucker Collins et al, “Transcriptional Regulation of Endothelial Cell Adhesion Molecules: NF-κB and Cytokine-Inducible Enhancers,” The FASEB Journal, vol. 9, pp. 899-909, 1995.
Patrick A. Baeuerle et al, “NF-κB as a Frequent Target for Immunosuppressive and Anti-Inflammatory Molecules,” Advances in Immunology, vol. 65, pp. 111-137, 1997.
Bruce J. Dezube et al, “Cytokine Dysregulation in AIDS: In Vivo Overexpression of mRNA of Tumor Necrosis Factor-α and Its Correlation with That of the Inflammatory Cytokine GRO,” Journal of Acquired Immune Deficiency Syndromes, vol. 5, pp. 1099-1104, 1992.
Gary Nabel et al, “An Inducible Transcription Factor Activates Expression of Human Immun odeficiency Virus in T Cells,” Nature, vol. 326, pp. 711-713, 1987.
Fatermeh Fazely et al, “Pentoifylline (Trental) Decreases the Replication of the Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Mononuclear Cells and in Cultured T Cells,” Blood, Vo. 77, No. 8, pp. 1653-1656, 1991.
Eduardo Munoz et al, “Activation of NF-κB by the Tax Protein of HTLV-1”, Immunobiol, vol. 193, pp. 128-136, 1995.
Nathalie Auphan et al, “Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis,” Science, vol. 270, pp. 286-290, 1995.
Rodney E. Shackelford et al, “Aspirin Inhibits Tumor Necrosis Factor-α Gene Expression in Murine Tissue Macrophages,” Molecular Pharmacology, vol. 52, pp. 421-429, 1997.
Vira Bitko et al, “Transcriptional Induction of Multiple Cytokines by Human Respiratory Syncytial Virus Requires Activation of NF-κB and is Inhibited by Sodium Salicylate and Aspirin,” Virology, vol. 232, pp. 369-378, 1997.
Kenji Suzuki et al, “2-Arylmethyl-1,4-benzoquinones. I. Novel Inhibitors of Platelet Aggregation: Synthesis and Pharmacological Evaluation,” Chem. Pharm. Bull, vol. 44, No. 1, pp. 139-144, 1996.
Mario C. Filion et al, “Anti-Inflammatory Activity of Cationic Lipids,” British Journal of Pharmacology, vol. 122, pp. 551-557, 1997.
Peter W. Tsao et al, “The Effect of Dexamethasone on the Expression of Activated NF-κB in Adjuvant Arthritis,” Clinical Immunology and Immunolopathology, vol. 83, No. 2, pp. 173-178, 1997.
Salvatore Cuzzocrea et al, “Antiinflammatory Effects of Mercaptoethylguanidine, A Combined Inhibitor of Nitric Oxide Synthase and Peroxynitrite Scavenger, in Carrageenan-Induced Models of Inflammation,” Free Radical Biology & Medicine, vol. 24, No. 3, pp. 450-459, 1998.
Yoshiki Sawa et al, “A Novel Strategy for Myocardial Protection Using In Vivo Tra

Affiliated with

Also associated with

Rating

NF-κB inhibitor comprising phenylmethyl benzoquinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NF-κB inhibitor comprising phenylmethyl benzoquinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NF-κB inhibitor comprising phenylmethyl benzoquinone... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3435050